Identification of Monosialylated N-glycoforms in the CDG Urinome by Ion Mobility Tandem Mass Spectrometry: The Potential for Clinical Applications
DOI: 10.1007/s12014-008-9010-3
© Humana Press 2008
Received: 11 March 2008
Accepted: 23 May 2008
Published: 14 August 2008
Abstract
Introduction
A novel approach of ion mobility tandem mass spectrometry (IMS-MS/MS) is applied to analysis of human glycourinome to obtain carbohydrate pattern data of congenital disorders of glycosylation patient. Overlapping of the complex carbohydrate mass range landscape has been highly reduced upon IMS-MS procedure, allowing more efficient identification by mapping and sequencing of glycan precursor ions, following their separation by mobility, according to difference in drift time through the traveling wave IMS cell. Intact and truncated N- and O-glycan structures modified by sialylation and fucosylation were identified according to their drift time separated molecular ions and submitted to fragmentation in a narrow mass window.
IMS CID MS/MS Analysis
The fragmentation spectra generated from the IMS separated precursor ions contain series of fragment ions maintaining the same mobility as their parent ions, and the assignment accuracy can be significantly enhanced.
Conclusion
According to the specific fragment ion patterns, carbohydrate epitopes described to be involved in pathological processes were assigned. A high potential of this glycomics-based strategy for clinical applications can be presented.
Keywords
Glycomics Glycoconjugates IMS MS Congenital disorders of glycosylationIntroduction
Congenital disorders of glycosylation (CDG) are a large family of genetic diseases resulting from defects in the synthesis of glycans and in the attachment of glycans to lipids and proteins. These disorders cause a wide range of clinically relevant human diseases with different, sometimes diffuse, clinical pictures. There are currently 12 defined N-, seven O- and three N- and O-glycosylation defects due to defects in proteins with glycosyltransferase or transport function already identified [1]. For a growing group of patients with unidentified defects, but typical and atypical clinical presentations in CDG, there is a high need for an increase in the speed and accuracy of diagnostics in order to design rational therapeutic suggestions in as short a time span as possible.
The alteration of glycan patterns related to CDG defects is reflected in the patients’ serum, which can be analyzed for glycosylation patterns of glycoproteins, according to proteomics-based protocols [2]. However, urine as a rich source of metabolic structures renders an excellent opportunity for noninvasive sample diagnostics. Carbohydrate patterns of CDG patients’ urine were investigated by us using distinct glycomics-based strategies to explore the feasibility of protocols and their potential for unique structure discovery and clinical applications [3–6]. Components of these highly complex mixtures depict different levels of modifications by sialylation and fucosylation. A high number of intact and truncated N- and O-glycan structures were revealed by high resolution mass spectrometry and correlated to the structures deposited in the databases [4]. Using a novel approach of ion mobility mass spectrometry (IMS-MS), overlapping of the carbohydrate mass range landscape was shown to be highly reduced, allowing development of strategies for more efficient identification by sequencing the glycan precursor ions, following their separation by their mobility, or drift time, through the traveling wave IMS cell [3]. The fragmentation data obtained clearly demonstrate that carbohydrate epitopes can be de novo identified by this type of bioanalysis rendering an efficient novel tool for glycomics to be introduced to the CDG research and be applied to clinical samples. In the following investigation, monosialylated glycoforms from urine and their terminal epitopes were identified by IMS and automatic data assignment to be correlated with those described in carbohydrate databases for comparison of their possible function.
Materials and Methods
Materials and Sample Preparation
Materials
Methanol was obtained from Merck (Darmstadt, Germany) and used without further purification. Graphitized carbon powder for the graphitized carbon cartridge preparation was collected by dismantling commercially available Active Charcoal MicroTip Columns 25-100 µl (Harvard Apparatus Inc). AG50 (H+) resin was purchased from Bio-Rad (Richmond, CA, USA). Distilled and deionized water (Mili-Q water systems Millipore, Bedford, MA, USA) was used for the preparation of the sample solutions.
CDG urine sample
The sample investigated in this study was a native glycoconjugate mixture from the urine of patient K.L. suffering from symptoms assigned to the congenital disorder of glycosylation (CDG). For isolation of components, the patient’s urine was filtered and submitted to a first gel filtration chromatography step on Biogel P2 followed by several chromatography stages as described previously [4, 5]. The fraction M3 from the patient K.L. was used in the present study.
Desalting of glycoconjugate mixtures
Prior to analysis by mass spectrometry, the fraction M3 containing a mixture of glycoconjugates was purified by homemade graphitized carbon cartridges as described previously [7] and desalted by AG50 (H+) resin.
Mass spectrometry
All measurements were performed on a Synapt high-definition mass spectrometry (HDMS) system (Waters, Manchester, UK). The Synapt HDMS is a hybrid quadrupole-triwave IMS-oa-TOF device. Gas-phase ions were generated by nano-electrospray ionization in the negative ion mode, passed through a quadrupole into the triwave cell where the ions were separated according to their mobility, and finally transferred to the oa-TOF mass analyzer [3]. Ion source conditions were optimized to minimize in-source fragmentation. DriftScope™ Mobility Environment software was used for ion mobility data visualization and manipulation. Instrumental control and mass spectra acquisition were operated by Waters MassLynx 4.1 software.
Collision-induced dissociation (CID) structural analysis of selected ionic species was performed by transfer T-Wave fragmentation [3]. The fragmentation pattern of sequenced glycoconjugates was assigned according to nomenclature introduced by Domon and Costello [8].
Data interpretation
The computer algorithm for mass spectrometry data interpretation was developed by using Borland Delphi 7 for Windows (Borland) [3]. All computational assignments have been performed within the mass accuracy range of 0–25 ppm.
Glycan database
Consortium for Functional Glycomics (http://www.functionalglycomics.org, 2008) and Glycosuite DB (https://tmat.proteomesystems.com/glycosuite, 2004) glycan databases has been used for correlation with proposed compositions by searching of structural information, such as the type and the number of monosaccharide building blocks. The list of previously described oligosaccharide structures related to the imported composition was generated as the output, providing information about the sample source, methods of structural elucidation, and the corresponding references.
Results
IMS-MS Glycoscreening of the KLM3 CDG Sample

Negative ion mode nanoESI oa-TOF MS of the fraction M3 obtained from urine of the patient KL after gel permeation chromatography. Spectrum was acquired from the TIC chromatogram over all mobility drift times. Inset: plot of the drift time vs. m/z values for the negative ion mode nanoESI oa-IMS-TOF MS. Ions have been distributed onto areas of predominantly singly (A), doubly (B), and triply (C) charged ionic species (selected by dashed lines). XIC chromatograms A, B, and C were generated from the corresponding area

Negative ion mode nanoESI oa-IMS-TOF MS of the sample KLM3 acquired over: a XIC chromatogram A, b XIC chromatogram B, and c XIC chromatogram C (Fig. 1, Inset)
Computer-assisted assignment of the major peaks detected in KLM3 sample by the negative ion nanoESI IMS oa-TOF MS
No. | [M-H]- | [M-2H]2- | [M-3H]3- | Proposed Composition | MWf | Referencesg |
---|---|---|---|---|---|---|
1 | 496.18 | HexHexNAcAsn | 497.19 | – | ||
2 | 544.20 | Hex2HexNAc | 545.20 | i | ||
3 | 602.21a | HexHexNAcThrPro | 581.24 | – | ||
4 | 599.21 | NeuAc2 | 600.20 | – | ||
5 | 632.21 | NeuAcHex2 | 633.21 | |||
6 | 655.23b | NeuAcHexHexNAc | 674.24 | |||
673.22 | ||||||
7 | 714.26 | NeuAcHexNAc2 | 715.27 | i | ||
8 | 769.26a | Hex2HexNAc2 | 748.27 | |||
9 | 760.27 | NeuAcHexHexNAcSer | 761.27 | |||
764.25c | ||||||
10 | 774.29 | NeuAcHexHexNAcThr | 775.29 | |||
778.26c | ||||||
11 | 809.25b | Hex5 | 828.27 | – | ||
12 | 819.29 | NeuAcdHexHexHexNAc | 820.30 | h | ||
13 | 835.29 | NeuAcHex2HexNAc | 836.29 | [29] | ||
14 | 873.34 | 436.16 | dHexHexNAc3Thr | 874.35 | – | |
15 | 876.30 | NeuAcHexHexNAc2 | 877.32 | |||
16 | 481.66 | NeuAc2HexHexNAc | 965.33 | |||
17 | 981.34 | NeuAcdHexHex2HexNAc | 982.35 | i | ||
18 | 997.33 | NeuAcHex3HexNAc | 998.34 | i | ||
19 | 1038.36 | NeuAcHex2HexNAc2 | 1039.37 | |||
20 | 1079.39 | NeuAcHexHexNAc3 | 1080.40 | i | ||
21 | 1125.38 | 562.19 | NeuAcHex2HexNAc2Ser | 1126.40 | – | |
22 | 1143.38 | NeuAcdHexHex3HexNAc | 1144.40 | – | ||
23 | 1152.41 | 575.69 | NeuAc2HexHexNAcSerThr | 1153.41 | – | |
24 | 1184.42 | 609.68d | NeuAcdHexHex2HexNAc2 | 1185.43 | i | |
25 | 1200.42 | 617.69d | NeuAcHex3HexNAc2 | 1201.42 | ||
26 | 1241.45 | NeuAcHex2HexNAc3 | 1242.45 | i | ||
27 | 1362.47 | 680.72 | NeuAcHex4HexNAc2 | 1363.48 | ||
698.71d | ||||||
28 | 1369.49b | NeuAcdHexHex2HexNAc3(-H2O) | 1388.51 | i | ||
29 | 1403.49 | 719.22d | NeuAcHex3HexNAc3 | 1404.50 | i | |
30 | 744.75b | NeuAcdHexHex4HexNAc2 | 1509.53 | – | ||
31 | 758.25 | NeuAcHex3HexNAc3Asn | 1518.54 | – | ||
32 | 1565.57 | 800.24d | NeuAcHex4HexNAc3 | 1566.55 | ||
33 | 803.76e | NeuAcdHexHex2HexNAc4 | 1591.59 | – | ||
812.75d | ||||||
34 | 839.29 | NeuAcHex4HexNAc3Asn | 1680.60 | – | ||
35 | 1727.60 | 881.27d | NeuAcHex5HexNAc3 | 1728.61 | ||
36 | 1768.64 | NeuAcHex4HexNAc4 | 1769.63 | h | ||
37 | 1930.65 | 982.81d | NeuAcHex5HexNAc4 | 1931.69 | ||
38 | 974.88 | NeuAcdHexHex3HexNAc4ThrPro | 1951.74 | – | ||
39 | 675.57 | NeuAcdHexHex4HexNAc4Asn | 2029.74 | – | ||
40 | 1055.85d | NeuAcdHexHex5HexNAc4 | 2077.74 | |||
41 | 1094.86 | NeuAcdHexHex5HexNAc4Asn | 2191.79 | – | ||
42 | 1150.92 | NeuAcdHexHex4HexNAc6 | 2303.84 | – | ||
43 | 791.94 | NeuAcHex4HexNAc7 | 2378.87 | – | ||
NeuAcdHex2Hex4HexNAc5Asn | 2378.87 | – | ||||
44 | 797.27 | NeuAcdHexHex5HexNAc5Asn | 2394.87 | – | ||
45 | 1199.93 | NeuAcdHexHex7HexNAc4 | 2401.85 | – | ||
46 | 845.96 | NeuAcHex5HexNAc7 | 2540.93 | – | ||
NeuAcdHex2Hex5HexNAc5Asn | 2540.93 | – | ||||
47 | 913.66 | NeuAcHex5HexNAc8 | 2744.00 | – | ||
NeuAcdHex2Hex5HexNAc6Asn | 2744.00 | – | ||||
48 | 967.67 | NeuAcHex6HexNAc8 | 2906.06 | – | ||
NeuAcdHex2Hex6HexNAc6Asn | 2906.06 | – |
All doubly charged ions obtained by averaging over region B were low abundant at the level of relative intensity below ~12% (Fig. 2b). According to the compositional analysis, 15 species out of 58 were assigned to free oligosaccharides (Table 1). Three doubly charged ions at m/z 758.25, 839.29, and 1094.86 were proposed to represent N-glycans linked to Asn and assigned as [NeuAcHex3HexNAc3Asn-2H]2−, [NeuAcHex4HexNAc3Asn-2H]2−, and [NeuAcdHexHex5HexNAc4Asn-2H]2−, respectively. Four doubly charged O-glycan species were proposed according to the compositional analysis to be linked at their respective reducing termini to Thr, Ser, Ser-Thr, or Thr-Pro. These are the ionic species detected at m/z 436.16, 562.19, 575.69, and 974.88 assigned to [dHexHexNAc3Thr-2H]2−, [NeuAcHex2HexNAc2Ser-2H]2−, [NeuAc2HexHexNAcSerThr-2H]2−, and [NeuAcdHexHex3HexNAc4ThrPro-2H]2−, respectively. In the doubly charged pool, the ions detected in the abundance range of 8–12% at m/z 469.15, 624.26, 930.89, and 1139.94 could not be assigned to any glycoconjugate structures; but, according to their CID MS/MS data, they could be assigned as collagen peptides containing a common Gly-Leu/Ile-Pro repeat (data not shown).
The data from region C produced 18 triply charged species with distinct isotopic distribution that were utilized for compositional analysis (Fig. 2c) and showed only six ionic species representing glycoconjugates (Table 1). Ionic species at m/z 675.57 and 797.27 were assigned to [NeuAcdHexHex4HexNAc4Asn-3H]3− and [NeuAcdHexHex5HexNAc5Asn-3H]3−, respectively. On the other hand, triply charged ions at m/z 791.94, 845.96, 913.66, and 967.67 could be simultaneously assigned to free oligosaccharides such as [NeuAcHex4HexNAc7–3H]3−, [NeuAcHex5HexNAc7–3H]3−, [NeuAcHex5HexNAc8–3H]3−, [NeuAcHex6HexNAc8–3H]3−, or Asn-linked N-glycans, such as [NeuAcdHex2Hex4HexNAc5Asn-3H]3−, [NeuAcdHex2Hex5HexNAc5Asn-3H]3−, [NeuAcdHex2Hex5HexNAc6Asn-3H]3−, and [NeuAcdHex2Hex6HexNAc6Asn-3H]3−, respectively (Table 1). The most intensive triply charged ions detected at m/z 759.66 below 2% abundance were assigned to a collagen peptide with Gly-Leu/Ile-Pro repeat (data not shown).
Thus, in total 138 ionic species with distinct isotopic distribution have been detected by IMS oa-TOF MS approach, and 47 singly and multiply charged species that previously overlapped became well separated using this approach.
IMS CID MS/MS Analysis

a Expansion of the mass range at m/z 1196–1208 of the negative ion mode nanoESI oa-TOF MS of the fraction KLM3, acquired from TIC chromatogram over all mobility drift times; b expansion of the mass range at m/z 1196–1208 of the spectrum acquired from XIC chromatogram of singly charged distributed area after IM separation; c Expansion of the mass range at m/z 1196–1208 of the spectrum acquired from XIC chromatogram of doubly charged distributed area after IM separation; d Plot of the drift time vs. m/z values for fragment ions obtained by CID of overlapped precursor ions at m/z 1199.93 (left) and 1200.42 (right); e Total ion current chromatogram with retained drift time of overlapped precursor ions at m/z 1199.93 (left) and 1200.42 (right). Selected areas indicate extracted ion current chromatogram A for the precursor ions at m/z 1200.42 and chromatogram B for the precursor ions at m/z 1199.93

Fragmentation pattern of the singly charged precursor ions at m/z 1200.42. The spectrum was obtained by averaging over XIC chromatogram A (Fig. 3e) after IMS separation. Inset: proposed structure—truncated sialylated biantennary N-glycan

a Negative ion mode nanoESI IMS oa-TOF MS/MS of the doubly charged precursor ions at m/z 1199.93. Fragmentation spectrum obtained by averaging over XIC chromatogram B (Fig. 3e) after IM separation. b Structural candidates proposed according to the rule of glycan biosynthesis and by the presence of diagnostic fragment ions
Ions at m/z 809.30 assigned to Hex5(-H2O) and m/z 1038.43 assigned to NeuAcHex2HexNAc2 were considered as “D” type and \({\text{C}}_{4\alpha } \) fragments, respectively, originating from the potential hybrid-type N-glycan isomer (Structure B, Fig. 5b). The double loss of a HexNAc unit from the parent ions detected at m/z 1994.72 indicates the absence of the core Fuc at the reducing end, and together with ions, indicating the presence of NeuAcLea/x antennae can support structural isomer D (Fig. 5b). Ions at m/z 1143.54 assigned to NeuAcdHexHex2HexNAc can be considered as “D+H2O” type fragment of the structural isomer, where the NeuAcLea/x antennae is distributed at Man6 of the N-glycan core region (Structure C, Fig. 5b). Among the proposed structures depicted, only the structure A (Fig. 5b), supported by the presence of \({\text{C}}_{4\alpha } \) at m/z 1200.46 has been found in the glycan database with a nonspecified source of origin (http://www.functionalglycomics.org, 2008).

a Negative ion mode nanoESI IMS oa-TOF MS/MS of the doubly charged precursor ions at m/z 1055.85. Fragmentation spectrum obtained by averaging over XIC chromatogram (Inset, dashed line); b structural candidates proposed according to the rule of glycan biosynthesis and by the presence of diagnostic fragment ions
Proposed structures carrying Sialyl T and Sialyl Lea/x associated epitopes found in KLM3 urinary sample

Since the significantly increased degree of core fucosylation of biantennary N-glycans as compared to normal has been reported in all so far known subtypes of CDG I [15], the validation of fucosylated oligosaccharides in the urine of CDG patient represents a potential direction for biomarker search.
Conclusions
Using the novel approach of ion mobility, separation coupled with tandem mass spectrometry intact and truncated N- and O-glycan structures from CDG patients’ urine can be de novo identified by mapping and sequencing. By automatic assignment, the composition of single species from the IMS-separated spectra, with reduced complexity, were shown to be accessible for structure correlations to those in databases. Through the use of IMS, the overlapping carbohydrate m/z landscape was highly reduced in given window, allowing the development of a highly efficient identification procedure by sequencing precursor ions, using transfer CID fragmentation after separation by IMS. Combining it with a previously proposed automated calculation procedure provides an efficient novel tool for glycomics to be introduced, and this can readily be applied to CDG research and clinical samples. Accordingly, different levels of sialylation and fucosylation can be analyzed and assigned to truncated and untruncated glycan structures containing possible clinically relevant epitopes.
Authors’ Affiliations
References
- Jaeken J, Matthijs G. Congenital disorders of glycosylation: a rapidly expanding disease family. Annu Rev Genomics Hum Genet 2007;8:261–78.PubMedView ArticleGoogle Scholar
- Šagi D, Kienz P, Denecke J, Marquardt T, Peter-Katalinić J. Glycoproteomics of N-glycosylation by in-gel deglycosylation and matrix-assisted laser desorption/ionisation-time of flight mass spectrometry mapping: application to congenital disorders of glycosylation. Proteomics 2005;5:2689–701.PubMedView ArticleGoogle Scholar
- Vakhrushev SY, Langridge J, Campuzano I, Hughes C, Peter-Katalinić J. Ion mobility mass spectrometry analysis of human glycourinome. Anal Chem 2008;80:2506–13.PubMedView ArticleGoogle Scholar
- Vakhrushev SY, Mormann M, Peter-Katalinić J. Identification of glycoconjugates in the urine of a patient with congenital disorder of glycosylation by high-resolution mass spectrometry. Proteomics 2006;6:983–92.PubMedView ArticleGoogle Scholar
- Vakhrushev SY, Zamfir A, Peter-Katalinić J. 0,2An cross-ring cleavage as a general diagnostic tool for glycan assignment in glycoconjugate mixtures. J Am Soc Mass Spectrom 2004;15:1863–8.PubMedView ArticleGoogle Scholar
- Zamfir A, Vakhrushev S, Sterling A, Niebel HJ, Allen M, Peter-Katalinić J. Fully automated chip-based mass spectrometry for complex carbohydrate system analysis. Anal Chem 2004;76:2046–54.PubMedView ArticleGoogle Scholar
- Packer NH, Lawson MA, Jardine DR, Redmond JW. A general approach to desalting oligosaccharides released from glycoproteins. Glycoconj J 1998;15:737–47.PubMedView ArticleGoogle Scholar
- Domon B, Costello CE. A systematic nomenclature for carbohydrate fragmentation in FAB MS/MS of glycoconjugates. Glycoconj J 1988;5:397–409.View ArticleGoogle Scholar
- Wheeler SF, Harvey DJ. Negative ion mass spectrometry of sialylated carbohydrates: discrimination of N-acetylneuraminic acid linkages by MALDI-TOF and ESI-TOF mass spectrometry. Anal Chem 2000;72:5027–39.PubMedView ArticleGoogle Scholar
- Nakamura Y, Takahashi Y, Yamaguchi S, et al. Severe infantile sialidosis–the characteristics of oligosaccharides isolated from the urine and the abdominal ascites. Tohoku J Exp.Med 1992;166:407–15.PubMedView ArticleGoogle Scholar
- Van Pelt J, Kamerling JP, Bakker HD, Vliegenthart JF. A comparative study of sialyloligosaccharides isolated from sialidosis and galactosialidosis urine. J Inherit Metab Dis 1991;14:730–40.PubMedView ArticleGoogle Scholar
- Šagi D, Peter-Katalinić J, Conradt HS, Nimtz M. Sequencing of tri- and tetraantennary N-glycans containing sialic acid by negative mode ESI QTOF tandem MS. J Am Soc Mass Spectrom 2002;13:1138–48.PubMedView ArticleGoogle Scholar
- Hard K, Van Zadelhoff G, Moonen P, Kamerling JP, Vliegenthart FG. The Asn-linked carbohydrate chains of human Tamm-Horsfall glycoprotein of one male. Novel sulfated and novel N-acetylgalactosamine-containing N-linked carbohydrate chains. Eur J Biochem 1992;209:895–915.PubMedView ArticleGoogle Scholar
- Dube DH, Bertozzi CR. Glycans in cancer and inflammation. Potential for therapeutics and diagnostics. Nat Rev Drug Discov 2005;4:477–88.PubMedView ArticleGoogle Scholar
- Callewaert N, Schollen E, Vanhecke A, Jaeken J, Matthijs G, Contreras R. Increased fucosylation and reduced branching of serum glycoprotein N-glycans in all known subtypes of congenital disorder of glycosylation I. Glycobiology 2003;13:367–75.PubMedView ArticleGoogle Scholar
- Parkkinen J, Finne J. Isolation and structural characterization of five major sialyloligosaccharides and a sialylglycopeptide from normal human urine. Eur J Biochem 1983;136:355–61.PubMedView ArticleGoogle Scholar
- Van Pelt J, Dorland L, Duran M, Hokke CH, Kamerling JP, Vliegenthart JF. Sialyl-alpha 2–6-mannosyl-beta 1–4-N-acetylglucosamine, a novel compound occurring in urine of patients with beta-mannosidosis. J Biol Chem 1990;265:19685–9.PubMedGoogle Scholar
- Amano J, Nishimura R, Mochizuki M, Kobata A. Comparative study of the mucin-type sugar chains of human chorionic gonadotropin present in the urine of patients with trophoblastic diseases and healthy pregnant women. J Biol Chem 1988;263:1157–65.PubMedGoogle Scholar
- Bhavanandan VP, Zhu Q, Yamakami K, et al. Purification and characterization of the MUC1 mucin-type glycoprotein, epitectin, from human urine: structures of the major oligosaccharide alditols. Glycoconj J 1998;15:37–49.PubMedView ArticleGoogle Scholar
- Gadroy P, Stridsberg M, Capon C, et al. Phosphorylation and O-glycosylation sites of human chromogranin A (CGA79–439) from urine of patients with carcinoid tumors. J Biol Chem 1998;273:34087–97.PubMedView ArticleGoogle Scholar
- Garver FA, Chang LS, Kiefer CR, et al. Localization of the carbohydrate units in a human immunoglobulin light chain, protein Sm lambda. Eur J Biochem 1981;115:643–52.PubMedView ArticleGoogle Scholar
- Irie F, Murakoshi H, Suzuki T, et al. Characterization of four monosialo and a novel disialo Asn N-glycosides from the urine of a patient with aspartylglycosaminuria. Glycoconj J 1995;12:290–7.PubMedView ArticleGoogle Scholar
- Van Pelt J, Van Bilsen DG, Kamerling JP, Vliegenthart JF. Structural analysis of O-glycosidic type of sialyloligosaccharide-alditols derived from urinary glycopeptides of a sialidosis patient. Eur J Biochem 1988;174:183–7.PubMedView ArticleGoogle Scholar
- Warner TG, Dekremer RD, Applegarth D, Mock AK. Diagnosis and characterization of GM2 gangliosidosis type-Ii (Sandhoff disease) by analysis of the accumulating N-acetyl-glucosaminyl oligosaccharides with high-performance liquid-chromatography. Clin Chim Acta 1986;154:151–64.PubMedView ArticleGoogle Scholar
- Strecker G, Herlantpeers MC, Fournet B, et al. Structure of seven oligosaccharides excreted in urine of a patient with sandhoffs disease (GM2 gangliosidosis-variant O). Eur J Biochem 1977;81:165–71.PubMedView ArticleGoogle Scholar
- Frösch M, Bindila LM, Baykut G, Allen M, Peter-Katalinić J, Zamfir AD. Coupling of fully automated chip electrospray to Fourier transform ion cyclotron resonance mass spectrometry for high-performance glycoscreening and sequencing. Rapid Commun Mass Spectrom 2004;18:3084–92.View ArticleGoogle Scholar
- Zamfir A, Peter-Katalinić J. Glycoscreening by on-line sheathless capillary electrophoresis/electrospray ionization-quadrupole time of flight-tandem mass spectrometry. Electrophoresis 2001;22:2448–57.PubMedView ArticleGoogle Scholar
- Hirabayashi Y, Matsumoto Y, Matsumoto M, et al. Isolation and characterization of major urinary amino acid O-glycosides and a dipeptide O-glycoside from a new lysosomal storage disorder (Kanzaki disease). Excessive excretion of serine- and threonine-linked glycan in the patient urine. J Biol Chem 1990;265:1693–701.PubMedGoogle Scholar
- Pollitt RJ, Pretty KM. The glycoasparagines in urine of a patient with aspartylglycosaminuria. Biochem J 1974;141:141–6.PubMedPubMed CentralView ArticleGoogle Scholar
- Escribano J, Lopex-Otin C, Hjerpe A, Grubb A, Mendez E. Location and characterization of the three carbohydrate prosthetic groups of human protein HC. FEBS Lett 1990;266:167–70.PubMedView ArticleGoogle Scholar
- Lecat D, Lemonnier M, Derappe C, et al. The structure of sialyl-glycopeptides of the O-glycosidic type, isolated from sialidosis (mucolipidosis I) urine. Eur J Biochem 1984;140:415–20.PubMedView ArticleGoogle Scholar
- Linden HU, Klein RA, Egge H, Peter-Katalinić J, Dabrowski J, Schindler D. Isolation and structural characterization of sialic-acid-containing glycopeptides of the O-glycosidic type from the urine of two patients with an hereditary deficiency in alpha-N-acetylgalactosaminidase activity. Biol Chem Hoppe Seyler 1989;370:661–72.PubMedView ArticleGoogle Scholar
- Amano J, Nishimura R, Sato S, Kobata A. Altered glycosylation of human chorionic gonadotropin decreases its hormonal activity as determined by cyclic-adenosine 3′,5′-monophosphate production in MA-10 cells. Glycobiology 1990;1:45–50.PubMedView ArticleGoogle Scholar
- de Beer T, van Zuylen CW, Hard K, et al. Rapid and simple approach for the NMR resonance assignment of the carbohydrate chains of an intact glycoprotein. Application of gradient-enhanced natural abundance 1H-13C HSQC and HSQC-TOCSY to the alpha-subunit of human chorionic gonadotropin. FEBS Lett 1994;348:1–6.PubMedView ArticleGoogle Scholar
- Weisshaar G, Hiyama J, Renwick AG. Site-specific N-glycosylation of human chorionic gonadotrophin–structural analysis of glycopeptides by one- and two-dimensional 1H NMR spectroscopy. Glycobiology 1991;1:393–404.PubMedView ArticleGoogle Scholar
- Nakano Y, Noda K, Endo T, Kobata A, Tomita M. Structural study on the glycosyl-phosphatidylinositol anchor and the asparagine-linked sugar chain of a soluble form of CD59 in human urine. Arch Biochem Biophys 1994;311:117–26.PubMedView ArticleGoogle Scholar